Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer

Field Value
Model ID12-040-01
Model NameRomond 2012
Pubmed ID22987084
First AuthorRomond
JournalJournal of Clinical Oncology
Year2012
TitleSeven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
Primary Index ConditionCancer
Secondary Index ConditionN/A
OutcomeMACE
Model Sample Size1830
Cohort Sample Size1830
Number of Events47
Follow-Up DurationLong (>6 months)
AUROC0.72
Calibration Reported1
CovariatesAge in years; Baseline percent LVEF
Mesh TermsTo be updated
Number of Validations0

External Validations